SCHEMBL6185563

SCHEMBL6185563

Cc1cccc(-c2nc(C(=O)O)[nH]c2-c2ccc3nnn(-c4ccccc4)c3c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.43
CSNK1D P48730 3/20 0.43
CSNK1E P49674 3/20 0.43
NT5E P21589 3/20 0.41
RPA1 P27694 1/20 0.40
PIN1 Q13526 2/20 0.39
PDE10A Q9Y233 1/20 0.38
HTT P42858 1/20 0.38
DHODH Q02127 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182069 0.93 NT5E (0.41) MAPK14CSNK1DCSNK1ENT5ERPA1
SCHEMBL6183056 0.93 MAPK14 (0.43) MAPK14CSNK1DCSNK1ENT5EPDE10A
SCHEMBL6188438 0.91 MAPK14 (0.45) MAPK14CSNK1DCSNK1ENT5EPDE10A
SCHEMBL6186458 0.89 NT5E (0.43) MAPK14NT5EPIN1L3MBTL1GAA
SCHEMBL6183189 0.84 MAPK14 (0.40) MAPK14CSNK1DCSNK1ENT5EGAA
SCHEMBL6186115 0.83 NT5E (0.42) MAPK14NT5EPIN1GAAHPGD
SCHEMBL6184613 0.83 KCNMA1 (0.43) MAPK14NT5EHTTALDH1A1NPC1
SCHEMBL6184681 0.81 NT5E (0.42) MAPK14NT5EGAAHPGD
SCHEMBL6184293 0.81 NT5E (0.41) MAPK14NT5EHTTDHODHALDH1A1
SCHEMBL6182974 0.80 MAPK14 (0.41) MAPK14CSNK1DCSNK1EPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 MAPK14 27/4885CSNK1D 1113/4885CSNK1E 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.